New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
OTC

ISOFRA

0,0125/Nasal Spray Solution/FRAMYCETINE
BOUCHARA RECORDATI
ManufacturerVerified lab

BOUCHARA RECORDATI

Public retail price
897.56DZD

Identification

Active ingredient (INN)
FRAMYCETINE
Internal code
22 E 014
Country of Origin
France
Pharmaceutical form
Nasal Spray Solution
Prescription List
OTC
Packaging
flacon/15ml
ISOFRA
Clinical View

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Description

A component of neomycin that is produced by Streptomyces fradiae.

On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed).

Indications

For the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis.

For the prophylaxis of ocular infections following foreign body removal

Pharmacodynamics

Framycetin is used for the treatment of bacterial eye infections such as conjunctivitis.

Framycetin is an antibiotic.

It is not active against fungi, viruses and most kinds of anaerobic bacteria.

Framycetin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth.

Framycetin is useful primarily in infections involving aerobic bacteria bacteria.

Mechanism of Action

16S ribosomal RNA (Enteric bacteria and other eubacteria) Inhibitor Small ribosomal subunit protein uS12 (Escherichia coli (strain K12)) Inhibitor.

Adverse Effects

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Alternatives